Stereotactic radiosurgery has been shown to afford a reasonable chance of local tumor control. However, new brain metastasis can arise following successful local tumor control from radiosurgery. This study evaluates the timing, number, and risk factors for development of subsequent new brain metastasis in a group of patients treated with stereotactic radiosurgery alone.
One hundred seventeen patients with histologically confirmed metastatic cancer underwent Gamma Knife surgery (GKS) to treat all brain metastases demonstrable on MR imaging. Patients were followed clinically and radiologically at approximately 3-month intervals for a median of 14.4 months (range 0.37–51.8 months). Follow-up MR images were evaluated for evidence of new brain metastasis formation. Statistical analyses were performed to determine the timing, number, and risk factors for development of new brain metastases.
The median time to development of a new brain metastasis was 8.8 months. Patients with 3 or more metastases at the time of initial radiosurgery or those with cancer histologies other than non–small cell lung carcinoma were found to be at increased risk for early formation of new brain metastasis (p < 0.05). The mean number of new metastases per patient was 1.6 (range 0–11). Those with a higher Karnofsky Performance Scale score at the time of initial GKS were significantly more likely to develop a greater number of brain metastases by the last follow-up evaluation.
The timing and number of new brain metastases developing in patients treated with GKS alone is not inconsequential. Those with 3 or more metastases at the time of radiosurgery and those with cancer histology other than non–small cell lung carcinoma were at greater risk of early formation of new brain metastasis. Frequent follow-up evaluations, such as at 3-month intervals, appears appropriate in this patient population, particularly in high-risk patients. When detected early, salvage treatments including repeat radiosurgery can be used to treat new brain metastasis.
Abbreviations used in this paper: GKS = Gamma Knife surgery; KPS = Karnofsky Performance Scale; NSCLC = non–small cell lung carcinoma; WBRT = whole-brain radiation therapy.
Address correspondence to: Jason P. Sheehan, M.D., Ph.D., Department of Neurological Surgery, University of Virginia Health System, Box 800212, Charlottesville, Virginia 22908. email: email@example.com.
Please include this information when citing this paper: published online March 12, 2010; DOI: 10.3171/2010.2.JNS091539.
AndrewsDWScottCBSperdutoPWFlandersAEGasparLESchellMC: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet363:1665–16722004
AoyamaHShiratoHTagoMNakagawaKToyodaTHatanoK: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA295:2483–24912006
AoyamaHTagoMKatoNToyodaTKenjyoMHirotaS: Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys68:1388–13952007
AtkinsMBSosmanJAAgarwalaSLoganTClarkJIErnstoffMS: Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer113:2139–21452008
ChangELWefelJSHessKRAllenPKLangFFKornguthDG: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol10:1037–10442009
JawaharAMatthewREMinagarAShuklaDZhangJHWillisBK: Gamma knife surgery in the management of brain metastases from lung carcinoma: a retrospective analysis of survival, local tumor control, and freedom from new brain metastasis. J Neurosurg100:842–8472004
LeeDHHanJYKimHTYoonSJPyoHRChoKH: Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer113:143–1492008
MeyersCASmithJABezjakAMehtaMPLiebmannJIllidgeT: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol22:157–1652004
MoscettiLNelliFFeliciARinaldiMDe SantisSD'AuriaG: Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer109:274–2812007
MuacevicAKrethFWHorstmannGASchmid-ElsaesserRWowraBSteigerHJ: Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg91:35–431999
RegineWFHuhnJLPatchellRASt ClairWHStrottmannJMeigooniA: Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys52:333–3382002
RegineWFScottCMurrayKCurranW: Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys51:711–7172001
SawrieSMGuthrieBLSpencerSANordalRAMeredithRFMarkertJM: Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys70:181–1862008
SheehanJPSunMHKondziolkaDFlickingerJLunsfordLD: Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg97:1276–12812002
SneedPKSuhJHGoetschSJSanghaviSNChappellRBuattiJM: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys53:519–5262002
VarlottoJMFlickingerJCNiranjanABhatnagarAKondziolkaDLunsfordLD: The impact of whole-brain radiation therapy on the long-term control and morbidity of patients surviving more than one year after gamma knife radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys62:1125–11322005
VarlottoJMFlickingerJCNiranjanABhatnagarAKKondziolkaDLunsfordLD: Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys57:452–4642003